Drug and radiation combo for recurrent pelvic endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of endometrial cancer that tests as pMMR (proficient mismatch repair).
- Your cancer has come back after surgery or cannot be removed, and it is only in the pelvis or vagina (not spread elsewhere).
- You have not had external radiation to your pelvis, vagina, or abdomen before.
- You are able to perform daily activities with some help (ECOG score 0 to 2).
- Your blood counts and liver, kidney, and heart function are within healthy limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
This study tests whether adding another drug to the standard combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) can help treat advanced or recurrent endometrial cancer that has already progressed after platinum-based chemotherapy. If you qualify, you may have access to a new treatment option while helping doctors learn what works best.
This trial tests a combination of two drugs (camrelizumab and anlotinib) for patients with a specific type of endometrial cancer that has returned or spread. The drug combo aims to boost your immune system to fight the cancer while also cutting off its blood supply. It is for patients whose tumor has a certain genetic feature and who have already tried chemotherapy.
Hear when a new Recurrent Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.